-
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
-
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
This is designated to validate patient-reported outcomes (PRO) measures in itch-specific pediatric skin conditions, such as atopic dermatitis, and examine the ability of a modified stigma instrument to assess the severity and type of stigma experienced in atopic dermatitis and other potentially stigmatizing conditions.
-
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).
-
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
The aim of the proposed study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
-
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
-
A Study of AK111 in Healthy Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose-escalation first-in human study to evaluate the safety, tolerability, PK, PD and immunogenicity of AK111 in healthy subjects following SC administration. The study will consist of cohorts of healthy subjects. Cohort 1, four unique subjects will be randomized to receive either active AK111 (N=3) or matching placebo (N=1). Cohorts 2, 3, 4 and 5, eight unique subjects will be randomized to receive either active AK111 (N=6) or matching placebo (N=2). Approximately 36 subjects will be treated in this study.
-
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. Two-hundred patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the Summary of Product Characteristics (SPC) of apremilast (Otezla®). Each patient will be followed up for a maximum of 24 months.
-
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
-
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
-
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
This multicenter, prospective, observational, single-arm, 26-week study will evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis with inadequate response to their current biologic agent regimen.
41 - 50 of 272 Trials
- Psoriasis
-
- Psoriatic Arthritis
-
- Psoriatic Disease
- Stay Healthy
-
Community
- icon:
Navigation CenterLink text:Get free, personalized guidance and support for psoriasis and psoriatic arthritis. - icon:
Talk PsoriasisLink text:The world’s online support community for those impacted by psoriasis or psoriatic arthritis. - icon:
One to OneLink text:Are you newly diagnosed? Have questions? Connect with someone who’s been through it. - icon:
Our SpotLink text:A new website for parents, kids and teens with psoriasis and psoriatic arthritis!
Stay Informed
- icon:
Health WebcastsLink text:Hear world-class experts provide the latest information on psoriatic disease.
-
- Get Involved
-
- Events and Programs
- icon:
Team NPFLink text:Join a group of everyday people dealing with psoriatic disease by walking, running, cycling and DIY-ing for a cure. - icon:
More than Skin DeepLink text:Outsmart psoriasis and psoriatic arthritis from the inside out at this local event.
-
- Research
-
- NPF Funded Research
- icon:
Victor Henschel BiobankLink text:A collection of biological samples and clinical information used by qualified scientists to advance the field of psoriasis genetics.
-
- Medical Professionals
-
- Stay Up-to-date
- icon:
Journal of Psoriasis and Psoriatic ArthritisLink text:Dedicated to providing practical information and research to those working in psoriatic disease care. - icon:
Continuing EducationLink text:Please join us at one of our educational events designed for health care providers.
-
